Abstract
Aim: To create a simple survival score for patients with high-grade gliomas based on clinical symptoms and performance status. Patients and Methods: Thirty-six patients received neurosurgical intervention followed by radiochemotherapy for high-grade gliomas. Six pre-treatment symptoms were included in the score depending on their impairment of quality of life, scoring each between 1 and 3. For each patient, the points from the symptoms were added and another 4 points were added for Karnofsky performance status (KPS) <80%. Based on the survival rates of these scores, two groups were formed: 1-4 (group A) and 5-12 points (group B). Results: The 1-, 2- and 3-year survival rates in group A were 100%, 33% and 24% in group A and 47%, 7% and 0% in group B (p<0.001). In addition, complete tumor resection (p<0.001) and tumor grade III (p<0.001) were associated with improved survival. Conclusion: A simple survival score was developed helping physicians in decisionmaking for patients with high-grade gliomas.
Original language | English (US) |
---|---|
Pages (from-to) | 689-693 |
Number of pages | 5 |
Journal | In Vivo |
Volume | 31 |
Issue number | 4 |
DOIs | |
State | Published - Jul 1 2017 |
Keywords
- Clinical symptoms
- High-grade gliomas
- Performance status
- Radiochemotherapy
- Survival score
- Temozolomide
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- Pharmacology